Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine I Chen

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Hematologic Malignancy Reports|December 21, 2012
Lenalidomide alone and in combination for chronic lymphocytic leukemiaChristine I Chen
Blood|August 4, 2023
Mitigating inequity: ethically prioritizing patients for CAR T-cell therapyJennifer A H Bell, Gregory A Jeffries, Christine I Chen
Current Hematologic Malignancy Reports|March 21, 2017
Current Review on High-Risk Multiple MyelomaHenry S H Chan, Christine I Chen, Donna E Reece
Current Oncology (Toronto, Ont.)|October 27, 2022
A Canadian Perspective on the Treatment of Waldenström MacroglobulinemiaRayan Kaedbey, Nicholas Forward, Laurie H Sehn, et al.
Kidney International Reports|June 2, 2018
Polyomavirus Nephropathy in Autologous Stem Cell TransplantationTushar Malavade, Clarissa Cassol, Rohan John, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
British Journal of Haematology|March 16, 2004
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplantHong Chang, Stephen Sloan, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials GroupChristine I Chen, C Tom Kouroukis, Darrell White, et al.
British Journal of Haematology|March 12, 2014
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemiaChristine I Chen, Harminder Paul, Trina Wang, et al.
British Journal of Haematology|April 19, 2013
D(T)PACE as salvage therapy for aggressive or refractory multiple myelomaAlina S Gerrie, Joseph R Mikhael, Lu Cheng, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Hematologic Malignancy Reports|December 21, 2012
Lenalidomide alone and in combination for chronic lymphocytic leukemiaChristine I Chen
Blood|August 4, 2023
Mitigating inequity: ethically prioritizing patients for CAR T-cell therapyJennifer A H Bell, Gregory A Jeffries, Christine I Chen
Current Hematologic Malignancy Reports|March 21, 2017
Current Review on High-Risk Multiple MyelomaHenry S H Chan, Christine I Chen, Donna E Reece
Current Oncology (Toronto, Ont.)|October 27, 2022
A Canadian Perspective on the Treatment of Waldenström MacroglobulinemiaRayan Kaedbey, Nicholas Forward, Laurie H Sehn, et al.
Kidney International Reports|June 2, 2018
Polyomavirus Nephropathy in Autologous Stem Cell TransplantationTushar Malavade, Clarissa Cassol, Rohan John, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
British Journal of Haematology|March 16, 2004
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplantHong Chang, Stephen Sloan, Dan Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2007
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials GroupChristine I Chen, C Tom Kouroukis, Darrell White, et al.
British Journal of Haematology|March 12, 2014
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemiaChristine I Chen, Harminder Paul, Trina Wang, et al.
British Journal of Haematology|April 19, 2013
D(T)PACE as salvage therapy for aggressive or refractory multiple myelomaAlina S Gerrie, Joseph R Mikhael, Lu Cheng, et al.
Pageof 3